Plaque Psoriasis: Zasocitinib vs. Deucravacitinib

We are studying whether a new oral medication, zasocitinib, is more effective than deucravacitinib for treating moderate-to-severe plaque psoriasis. The trial will also assess the safety and tolerability of both treatments.

6-12 months 6-10 visits Confirmation phase (III)Post-Trial Drug Access Cost Reimbursement Investigational Medicines OralDermatology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Deucravacitinib

Deucravacitinib is a substance that blocks a specific immune enzyme to lower inflammation, mainly used for moderate-to-severe plaque psoriasis.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Zasocitinib

Sotyktu

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Multiprofile Hospital For Active Treatment Dr. Tota Venkova AD

Department of Dermatology and Venerology

Gabrovo, Bulgaria

Diagnostics And Consultancy Center Sveti Georgi EOOD

Haskovo, Bulgaria

Medical Center Medconsult Pleven OOD

Lovech, Bulgaria

Sponsor: Takeda Development Center Americas Inc.

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.